Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study
The Lancet Neurology
Fecha de publicación: 29 august 2018
DOI: https://doi.org/10.1016/S1474-4422(18)30285-0
Autores: Juan Fortea, PhD., María Carmona-Iragui, PhD., Bessy Benejam, MSc., Susana Fernández, MD., Laura Videla, MSc., Isabel Barroeta, PhD., Daniel Alcolea, PhD., Jordi Pegueroles, MSc., Laia Muñoz, MSc
Olivia Belbin, PhD., Mony J de Leon, EdD., et al.
Background: Diagnosis of Alzheimer’s disease in Down syndrome is challenging because of the absence of validated diagnostic biomarkers. We investigated the diagnostic performance of plasma and CSF biomarkers in this population.
